Log in with your email address username.


[Correspondence] Sirolimus for systemic lupus erythematosus – Authors’ reply

We thank Hannah Q Hu and colleagues for their Correspondence. As described in the title and throughout the paper, our study was an open-label trial.1 Consequently, follow-up double-blind placebo-controlled trials are warranted. This need was repeatedly stated in the abstract and discussion, where we also suggested the need to include a more diverse patient population, since the completed study primarily involved white females.